27PD - Plasma miRNA-based signatures to predict 3-year postoperative recurrence risk for patients with stage II and III gastric cancer

Date 21 December 2015
Event ESMO Asia 2015 Congress
Session Basic Science, biomarkers, new diagnostics and translational research
Topics Gastric Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Xinyang Liu
Citation Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518
Authors X. Liu1, X. Zhang2, Z. Zhang2, J. Chang2, Z. Wu2, C. Wang2, Z. Sun2, X. Ge2, R. Geng2, W. Tang2, C. Dai2, Y. Lin2, M. Sun3, W. Jia4, W. Xue4, Y. Hu5, J. Li6
  • 1Clinical Medicine (8-year Program), Fudan University Shanghai Medical College, 200032 - Shanghai/CN
  • 2Medical Oncology, Shanghai Cancer Center Fudan University, Shanghai/CN
  • 3Pathology, Shanghai Cancer Center Fudan University, Shanghai/CN
  • 4Medical Oncology, Cancer Centre Sun Yat-Sen University, Guangzhou/CN
  • 5Tissue Bank, Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing/CN
  • 6Medical Oncology, Shanghai Tianyou Hospital of Tongji University, Shanghai/CN



Our aim was to identify plasma microRNA (miRNA)-based signatures to predict 3-year postoperative recurrence risk for patients with stage II and III Gastric cancer (GC) so as to provide insights for individualized adjunctive therapy.


Plasma miRNA expression was investigated in three phases including 407 patients recruited from three centers. ABI miRNA microarray and TaqMan Low Density Array (TLDA) were adopted in the discovery phase to identify potential miRNAs. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was used to assess the expression of selected miRNAs. Logistic regression models were constructed in the training set (n = 170) and validated in the validation set (n = 169). Receiver operating characteristic (ROC) analyses, survival analyses and subgroup analyses were further used to assess the accuracy of the models.


We identified a 7 miRNA classifier and 7miR + pathological factors index, that provided high predictive accuracy on GC recurrence (area under the curve (AUC) = 0.725 and 0.841 in the training set; 0.627 and 0.771 in the validation set). Signatures defined high-risk patients showed significantly shorter disease-free survival (DFS) and overall survival (OS) than low-risk patients. The 7 miRNA classifier is an independent prognostic factor, and could add predictive value to traditional prognostic factors. Subgroup analyses revealed the satisfactory performance persisted regardless of stage, and the two models both displayed high accuracy in stage IIA patients.


The signatures are reliable prognostic and predictive tools for disease recurrence in patients with stage II and III GC.

Clinical trial identification


All authors have declared no conflicts of interest.